Director Kevin Charles Gorman sold nearly $14.6 million in Neurocrine Biosciences (NBIX) shares across two open market transactions in the past year, with his most recent sale on August 7, 2025. These NBIX insider sales rank 858th among nearly 12,000 individuals averaging $8.6 million per person over 6 trades. He also sold $29,255 of Xencor (XNCR) shares once on June 16, 2025, ranking 10,837th. No open market purchases recorded.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | F | Common Stock | 3024 | $124.12 | 519,473.0000 | 102,500,000 | 0.58% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Common Stock | 5377 | $0.00 | 524,850.0000 | 102,500,000 | 1.04% | 0.01% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | F | Common Stock | 2901 | $124.12 | 521,949.0000 | 102,500,000 | 0.55% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Restricted Stock Unit | 5377 | $0.00 | 5,377.0000 | 102,500,000 | 50.00% | 0.01% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Restricted Stock Unit | 5604 | $0.00 | 11,208.0000 | 102,500,000 | 33.33% | 0.01% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | F | Common Stock | 34380 | $124.12 | 551,293.0000 | 102,500,000 | 5.87% | 0.03% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | A | Common Stock | 63724 | $0.00 | 585,673.0000 | 102,500,000 | 12.21% | 0.06% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Common Stock | 5604 | $0.00 | 522,497.0000 | 102,500,000 | 1.08% | 0.01% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Restricted Stock Unit | 5142 | $0.00 | 0.0000 | 102,500,000 | 100.00% | 0.01% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | F | Common Stock | 2845 | $136.06 | 516,893.0000 | 102,500,000 | 0.55% | 0.00% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Common Stock | 5142 | $0.00 | 519,738.0000 | 102,500,000 | 1.00% | 0.01% |
| Aug. 7, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Non-Qualified Stock Option | 106322 | $0.00 | 0.0000 | 103,700,000 | 100.00% | 0.10% |
| Aug. 7, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | S | Common Stock | 106322 | $126.41 | 514,596.0000 | 103,700,000 | 17.12% | 0.10% |
| Aug. 7, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Common Stock | 106322 | $35.99 | 620,918.0000 | 103,700,000 | 20.66% | 0.10% |
| June 12, 2025 | Xencor Inc | $XNCR | GORMAN KEVIN CHARLES | Director | A | Common Stock | 13686 | $0.00 | 22,078.0000 | 65,041,265 | 163.08% | 0.02% |
| June 16, 2025 | Xencor Inc | $XNCR | GORMAN KEVIN CHARLES | Director | S | Common Stock | 3173 | $9.22 | 18,905.0000 | 65,041,265 | 14.37% | 0.00% |
| June 12, 2025 | Xencor Inc | $XNCR | GORMAN KEVIN CHARLES | Director | A | Stock Option (Right to Buy) | 27372 | $0.00 | 27,372.0000 | 65,041,265 | 9999.99% | 0.04% |
| May 27, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | S | Common Stock | 9613 | $120.38 | 514,596.0000 | 103,700,000 | 1.83% | 0.01% |
| May 21, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | A | Non-Qualified Stock Option | 6610 | $0.00 | 6,610.0000 | 103,700,000 | 9999.99% | 0.01% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Restricted Stock Unit | 5376 | $0.00 | 10,754.0000 | 103,700,000 | 33.33% | 0.01% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Restricted Stock Unit | 5603 | $0.00 | 16,812.0000 | 103,700,000 | 25.00% | 0.01% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | S | Common Stock | 2832 | $116.69 | 521,618.0000 | 103,700,000 | 0.54% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | S | Common Stock | 3012 | $116.68 | 524,209.0000 | 103,700,000 | 0.57% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Common Stock | 5376 | $0.00 | 524,450.0000 | 103,700,000 | 1.04% | 0.01% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Common Stock | 5603 | $0.00 | 527,221.0000 | 103,700,000 | 1.07% | 0.01% |
| Feb. 8, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Restricted Stock Unit | 4318 | $0.00 | 0.0000 | 103,700,000 | 100.00% | 0.00% |
| Feb. 10, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | S | Common Stock | 2274 | $118.37 | 519,074.0000 | 103,700,000 | 0.44% | 0.00% |
| Feb. 8, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Common Stock | 4318 | $0.00 | 521,348.0000 | 103,700,000 | 0.84% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | S | Common Stock | 2707 | $152.92 | 517,030.0000 | 103,700,000 | 0.52% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Common Stock | 5141 | $0.00 | 519,737.0000 | 103,700,000 | 1.00% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Restricted Stock Unit | 5141 | $0.00 | 5,142.0000 | 103,700,000 | 50.00% | 0.00% |
| Jan. 27, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Non-Qualified Stock Option | 146105 | $0.00 | 0.0000 | 103,700,000 | 100.00% | 0.14% |
| Jan. 27, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | M | Common Stock | 146105 | $32.99 | 660,701.0000 | 103,700,000 | 28.39% | 0.14% |
| Jan. 27, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Director | S | Common Stock | 146105 | $149.46 | 514,596.0000 | 103,700,000 | 22.11% | 0.14% |
| Sept. 27, 2024 | Xencor Inc | $XNCR | GORMAN KEVIN CHARLES | Director | S | Common Stock | 2654 | $20.68 | 8,392.0000 | 60,503,283 | 24.03% | 0.00% |
| June 13, 2024 | Xencor Inc | $XNCR | GORMAN KEVIN CHARLES | Director | A | Stock Option (Right to Buy) | 11971 | $0.00 | 11,971.0000 | 60,503,283 | 9999.99% | 0.02% |
| June 13, 2024 | Xencor Inc | $XNCR | GORMAN KEVIN CHARLES | Director | A | Common Stock | 5986 | $0.00 | 11,046.0000 | 60,503,283 | 118.30% | 0.01% |
| Feb. 13, 2024 | Xencor Inc | $XNCR | GORMAN KEVIN CHARLES | Director | P | Common Stock | 53 | $19.12 | 5,060.0000 | 60,503,283 | 1.06% | 0.00% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 2832 | $133.02 | 514,596.0000 | 101,000,000 | 0.55% | 0.00% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | A | Restricted Stock Unit | 22415 | $0.00 | 22,415.0000 | 101,000,000 | 9999.99% | 0.02% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | A | Stock Option | 112644 | $0.00 | 112,644.0000 | 101,000,000 | 9999.99% | 0.11% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | M | Common Stock | 2312 | $43.24 | 512,052.0000 | 101,000,000 | 0.45% | 0.00% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | M | Incentive Stock Option | 2778 | $35.99 | 0.0000 | 101,000,000 | 100.00% | 0.00% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | M | Incentive Stock Option | 2312 | $43.24 | 0.0000 | 101,000,000 | 100.00% | 0.00% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | M | Common Stock | 2778 | $35.99 | 509,740.0000 | 101,000,000 | 0.55% | 0.00% |
| Feb. 8, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 2274 | $134.15 | 506,962.0000 | 101,000,000 | 0.45% | 0.00% |
| Feb. 6, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 3040 | $142.18 | 504,919.0000 | 101,000,000 | 0.60% | 0.00% |
| Jan. 31, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 2707 | $140.69 | 502,188.0000 | 101,000,000 | 0.54% | 0.00% |
| Jan. 8, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 105835 | $132.44 | 499,754.0000 | 101,000,000 | 17.48% | 0.10% |
| Jan. 9, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | M | Common Stock | 62023 | $19.59 | 561,777.0000 | 101,000,000 | 12.41% | 0.06% |
| Jan. 9, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 62023 | $134.01 | 499,754.0000 | 101,000,000 | 11.04% | 0.06% |
| Jan. 9, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | M | Non-Qualified Stock Option | 62023 | $19.59 | 0.0000 | 101,000,000 | 100.00% | 0.06% |
| Jan. 8, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | M | Non-Qualified Stock Option | 105835 | $19.59 | 62,023.0000 | 101,000,000 | 63.05% | 0.10% |
| Jan. 8, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | M | Common Stock | 105835 | $19.59 | 605,589.0000 | 101,000,000 | 21.18% | 0.10% |
| Aug. 21, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 9328 | $107.40 | 499,754.0000 | 98,900,000 | 1.83% | 0.01% |
| June 20, 2023 | Xencor Inc | $XNCR | GORMAN KEVIN CHARLES | Director | A | Stock Option (Right to Buy) | 10013 | $0.00 | 10,013.0000 | 59,652,461 | 9999.99% | 0.02% |
| June 20, 2023 | Xencor Inc | $XNCR | GORMAN KEVIN CHARLES | Director | A | Common Stock | 5007 | $0.00 | 5,007.0000 | 59,652,461 | 9999.99% | 0.01% |
| Feb. 13, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | A | Stock Option | 133656 | $0.00 | 133,656.0000 | 98,900,000 | 9999.99% | 0.14% |
| Feb. 13, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | A | Restricted Stock Unit | 21506 | $0.00 | 21,506.0000 | 98,900,000 | 9999.99% | 0.02% |
| Feb. 7, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 20482 | $102.43 | 489,322.0000 | 98,900,000 | 4.02% | 0.02% |
| Feb. 6, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 3040 | $105.68 | 468,008.0000 | 98,900,000 | 0.65% | 0.00% |
| Feb. 7, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 3248 | $102.30 | 470,930.0000 | 98,900,000 | 0.68% | 0.00% |
| Feb. 8, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 2274 | $104.30 | 491,365.0000 | 98,900,000 | 0.46% | 0.00% |
| Jan. 31, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | GORMAN KEVIN CHARLES | Chief Executive Officer | S | Common Stock | 2707 | $110.08 | 465,278.0000 | 98,900,000 | 0.58% | 0.00% |